Compare MIRM & FRSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | FRSH |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | 2019 | 2021 |
| Metric | MIRM | FRSH |
|---|---|---|
| Price | $79.34 | $12.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 16 |
| Target Price | ★ $92.45 | $19.53 |
| AVG Volume (30 Days) | 809.5K | ★ 3.1M |
| Earning Date | 11-04-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $471,794,000.00 | ★ $810,640,000.00 |
| Revenue This Year | $53.78 | $18.20 |
| Revenue Next Year | $19.91 | $13.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.66 | 18.18 |
| 52 Week Low | $36.88 | $10.51 |
| 52 Week High | $82.58 | $19.77 |
| Indicator | MIRM | FRSH |
|---|---|---|
| Relative Strength Index (RSI) | 62.33 | 47.87 |
| Support Level | $77.99 | $12.11 |
| Resistance Level | $82.58 | $12.48 |
| Average True Range (ATR) | 3.21 | 0.32 |
| MACD | 1.03 | -0.08 |
| Stochastic Oscillator | 83.25 | 12.10 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions.